Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study-Reference-Cited by-同舟云学术

Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study

Published:2017-10 Issue: Volume:61 Page:10-17
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Frairia Chiara,Aydin Semra,Audisio Ernesta,Riera Ludovica,Aliberti Sabrina,Allione Bernardino,Busca Alessandro,D'Ardia Stefano,Dellacasa Chiara Maria,Demurtas Anna,Evangelista Andrea,Ciccone Giovannino,Francia di Celle Paola,Nicolino Barbara,Stacchini Alessandra,Marmont Filippo,Vitolo Umberto

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference30 articles.

1. What does MRD in leukemia really mean?;Goldman;Leukemia,2014

2. Assessment of minimal residual disease in acute myeloid leukemia;Grimwade;Curr. Opin. Oncol.,2010

3. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia;Buccisano;Blood,2012

4. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects;van der Velden;Leukemia,2003

5. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia;Corbacioglu;J. Clin. Oncol.,2010

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. WT1 Expression Is Associated with Poor Overall Survival after Azacytidine and DLI in a Cohort of Adult AML and MDS Patients;Cancers;2024-09-04

2. Wilms’ tumor gene 1 in hematological malignancies: friend or foe?;Hematology;2023-09-05

3. Persistence of ex vivo expanded tumour and pathogen specific T-cells after allogeneic stem cell transplant for myeloid malignancies (the INTACT study);2023-06-02

4. MRD-directed and risk-adapted individualized stratified treatment of AML;Chinese Journal of Cancer Research;2023

5. The present and future of measurable residual disease testing in acute myeloid leukemia;Haematologica;2022-12-01